Search Results - "Kharat, Akshay"

Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease by Coleman, Craig I., Kharat, Akshay A., Bookhart, Brahim, Baker, William L.

“…To perform a systematic literature review and indirect treatment comparison (ITC) to identify, summarize and quantify randomized controlled trial (RCT)…”
Get full text

1150-P: Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal Outcomes in Patients with Type 2 Diabetes and Proteinuria by COLEMAN, CRAIG I., WEEDA, ERIN R., KHARAT, AKSHAY A., BOOKHART, BRAHIM, BAKER, WILLIAM L.

“…Background: The impact of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) on renal outcomes in patients with type 2…”
Get full text

Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US by Ammann, Eric M., O’Brien, Ellen S., Milentijevic, Dejan, Kharat, Akshay A., Talbot, Darren A., Canovatchel, William, Haskell, Lloyd, Andrawis, Nabil S.

“…Per treatment guidelines, resistant hypertension is defined as uncontrolled blood pressure (BP) while taking 3 concomitant antihypertensives (AHTs) or…”
Get full text

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma by Jagannath, Sundar, Joseph, Nedra, Crivera, Concetta, Kharat, Akshay, Jackson, Carolyn C., Valluri, Satish, Cost, Patricia, Phelps, Hilary, Slowik, Rafal, Klein, Timothy, Smolen, Lee, Yu, Xueting, Cohen, Adam D.

“…Introduction Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell…”
Get full text

Assessing disparities in the receipt of inhaled corticosteroid prescriptions for asthma by Hispanic and non-Hispanic white patients by Kharat, Akshay A, Borrego, Matthew E, Raisch, Dennis W, Roberts, Melissa H, Blanchette, Christopher M, Petersen, Hans

“…Inhaled corticosteroids (ICS) are widely used in the management of asthma. Prior research suggests that access to ICS among patients with asthma may vary by…”
Get full text

Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States by Shah, Anshul, Dabbous, Firas, Shah, Surbhi, Ashton, Veronica, Kharat, Akshay

“…The objective in this study was to assess the clinical and economic implications of the inclusion of rivaroxaban as a secondary prophylaxis in patients with…”
Get more information

Risk factors for recurrent venous thromboembolism: a real-world analysis by Fu, Alex Z., Feng, Xue, Ashton, Veronica, Kharat, Akshay

“…This study was conducted in patients treated for initial venous thromboembolism (VTE) for approximately 6 months to enhance understanding of the risk factors…”
Get full text

Real-World Incidence of Adverse Clinical Outcomes Among People With Coronary Artery Disease and/or Peripheral Artery Disease in Relation to Vascular Risk in the United States by Desai, Urvi, Babcock, Aram, Wang, Yao, Akbarnejad, Hanane, Lemus Wirtz, Esteban, Laliberte, Francois, Lefebvre, Patrick, Kharat, Akshay

“…Presence of polyvascular disease, diabetes, heart failure, or renal insufficiency in patients with chronic coronary artery disease (CAD) and peripheral artery…”
Get full text

Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy by Alberts, Mark J., Zhdanava, Maryia, Pilon, Dominic, Caron-Lapointe, Gabrielle, Lefebvre, Patrick, Bookhart, Brahim, Kharat, Akshay

“…OBJECTIVESTo compare the risk of stroke and systemic embolism (SE) among patients with nonvalvular atrial fibrillation (NVAF) who abandoned their first direct…”
Get full text

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy by Alberts, Mark J., He, Jinghua, Kharat, Akshay, Ashton, Veronica

“…Background Current evidence suggests that rivaroxaban may be well tolerated and effective in patients with nonvalvular atrial fibrillation (NVAF) and obesity;…”
Get full text

Risk factors for recurrent venous thromboembolism: a real-world analysis by Fu, Alex Z., Feng, Xue, Ashton, Veronica, Kharat, Akshay

“…This study was conducted in patients treated for initial venous thromboembolism (VTE) for approximately 6 months to enhance understanding of the risk factors…”
Get full text

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study by Alberts, Mark, Zhdanava, Maryia, Pilon, Dominic, Caron-Lapointe, Gabrielle, Lefebvre, Patrick, Bookhart, Brahim, Kharat, Akshay

“…Background Direct oral anticoagulants (DOACs) are the American Society of Hematology guideline-recommended treatment for venous thromboembolism (VTE) in the…”
Get full text

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation by Alberts, Mark, Zhdanava, Maryia, Pilon, Dominic, Caron-Lapointe, Gabrielle, Lefebvre, Patrick, Bookhart, Brahim, Kharat, Akshay

“…Introduction Direct oral anticoagulants (DOACs) are essential in ischemic stroke/systemic embolism (SE) prevention among patients with nonvalvular atrial…”
Get full text

POSTER: MM-613 Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy by Jagannath, Sundar, Kharat, Akshay, Fu, Alex, Huo, Stephen, Kohli, Monal, Adams, Shayna, Umeh, Emeka, Foster, Miran

Get full text

P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States by Hansen, Doris, Kharat, Akshay, Potluri, Ravi, Patidar, Sanjog, Huo, Stephen, Khouri, Jack

Get full text

POSTER: MM-619 Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States by Hansen, Doris, Kharat, Akshay, Potluri, Ravi, Patidar, Sanjog, Huo, Stephen, Khouri, Jack

Get full text

P-276 Healthcare resource utilization and costs among patients with relapsed/refractory multiple myeloma treated with chimeric antigen receptor-T (CAR-T) cell therapy by Jagannath, Sundar, Kharat, Akshay, Fu, Alex, Huo, Stephen, Kohli, Monal, Adams, Shayna, Umeh, Emeka, Foster, Miran

Get full text

MM-619 Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States by Hansen, Doris, Kharat, Akshay, Potluri, Ravi, Patidar, Sanjog, Huo, Stephen, Khouri, Jack

“…Multiple therapies are available for multiple myeloma (MM) treatment across the proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 antibody…”
Get full text

MM-613 Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy by Jagannath, Sundar, Kharat, Akshay, Fu, Alex, Huo, Stephen, Kohli, Monal, Adams, Shayna, Umeh, Emeka, Foster, Miran

“…Chimeric antigen receptor-T cell (CAR-T) therapies have furthered multiple myeloma (MM) treatment, but healthcare resource utilization (HCRU) and costs for…”
Get full text

Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study by Alberts, Mark, Zhdanava, Maryia, Pilon, Dominic, Caron-Lapointe, Gabrielle, Lefebvre, Patrick, Bookhart, Brahim, Kharat, Akshay

“…Introduction Among patients with venous thromboembolism (VTE), direct oral anticoagulants (DOACs) are recommended for preventing thromboembolic recurrence,…”
Get full text